This article was originally published in The Gray Sheet
InforMax' Vector and Vector NTI family of products will simplify use of Invitrogen's kits for gene identification, cloning, expression and analysis, under a $42 mil. all-cash transaction, expected to close by year-end, the firms say. InforMax President, Chairman and CEO Andrew Whiteley will remain president of InforMax. Tender offer will give Invitrogen 100% of InforMax outstanding common stock, valued at $1.36 per share...
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.